Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Front Immunol. 2022 Nov 14;13:1035402. doi: 10.3389/fimmu.2022.1035402. eCollection 2022.
Breast cancer is the most common cancer in women worldwide and is a substantial public health problem. Screening for breast cancer mainly relies on mammography, which leads to false positives and missed diagnoses and is especially non-sensitive for patients with small tumors and dense breasts. The prognosis of breast cancer is mainly classified by tumor, node, and metastasis (TNM) staging, but this method does not consider the molecular characteristics of the tumor. As the product of the immune response to tumor-associated antigens, autoantibodies can be detected in peripheral blood and can be used as noninvasive, presymptomatic, and low-cost biomarkers. Therefore, autoantibodies can provide a possible supplementary method for breast cancer screening and prognosis classification. This article introduces the methods used to detect peripheral blood autoantibodies and the research progress in the screening and prognosis of breast cancer made in recent years to provide a potential direction for the examination and treatment of breast cancer.
乳腺癌是全球女性最常见的癌症，也是一个重大的公共卫生问题。乳腺癌的筛查主要依赖于乳房 X 光摄影术，但这种方法会导致假阳性和漏诊，并且对肿瘤较小和乳腺致密的患者尤其不敏感。乳腺癌的预后主要通过肿瘤、淋巴结和转移 (TNM) 分期来分类，但这种方法不考虑肿瘤的分子特征。作为针对肿瘤相关抗原的免疫反应的产物，自身抗体可以在外周血中被检测到，并可用作非侵入性、无症状和低成本的生物标志物。因此，自身抗体可以为乳腺癌的筛查和预后分类提供一种可能的补充方法。本文介绍了检测外周血自身抗体的方法，以及近年来在乳腺癌筛查和预后方面的研究进展，为乳腺癌的检查和治疗提供了一个潜在的方向。
